Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). 


The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.

Good, Coric named 2017 CURE Entrepreneurs of the Year
In a ceremony December 12 at the CURE Annual Holiday Party at Alexion in New Haven, the 2017 CURE Entrepreneur of the Year award was presented to Jennifer Good of Trevi Therapeutics and Dr. Vlad Coric of Biohaven Pharmaceuticals, two biotechnology ex...
Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer
Highly experienced clinical drug developer to oversee R&D functions and Companys Phase 3 development program